Skip to main content

Table 1 Demographics of selected participants from the ADNI cohort

From: The accuracy and robustness of plasma biomarker models for amyloid PET positivity

 

Aβ PET negative (n = 58)

Aβ PET positive (n = 60)

P value

Age, years, median (IQR)

70.8 (66.5, 75.7)

73.8 (69.9, 77.4)

0.14

Clinical diagnosis, n (CU/CI)

30/28

20/40

0.04

Female, n (%)

24 (41.4%)

26 (43.3%)

0.98

Years of education, median (IQR)

18.0 (14.2, 18.0)

16.0 (14.0, 18.0)

0.33

APOE-ε4 carriers, n (%)

15 (25.9%)

32 (53.3%)

< 0.01

MMSE score, median (IQR)

29.0 (28.0, 30.0)

27.5 (24.0, 29.2)

< 0.0001

Florbetapir, global SUVR, median (IQR)

1.00 (0.954, 1.03)

1.33 (1.22, 1.46)

< 0.0001

42/40 IP-MS, median (IQR)

0.132 (0.128, 0.141)

0.122 (0.117, 0.127)

< 0.0001

42/40 Simoa, median (IQR)

0.050 (0.043, 0.054)

0.044 (0.040, 0.048)

< 0.01

GFAP, pg/mL, median (IQR)

113 (80.7, 154)

164 (125, 223)

< 0.001

P-tau181, pg/mL, median (IQR)

11.7 (8.2, 17.2)

18.8 (13.1, 23.0)

< 0.01

NfL, pg/mL, median (IQR)

23.6 (17.7, 36.1)

31.5 (24.8, 40.1)

0.04

  1. Data shown as median (IQR; interquartile range) or n (%), as appropriate. Continuous variables were compared using t test and Pearson’s chi-square to compare frequencies of categorical variables between groups. As further explained, Aβ42/40 IP-MS corresponds to the IP-MS assay from Washington University whilst Aβ42/40 Simoa refers to the measurements from the Simoa Neuro 4-plex E assay
  2. Abbreviations: amyloid-β, CU cognitively unimpaired, CI mild cognitive impairment, MMSE Mini-Mental State Examination, NfL neurofilament light chain, P-tau181 tau phosphorylated at threonine 181, SD standard deviation, SUVR standardized uptake value ratio